ALNY

Alnylam Pharmaceuticals, Inc. develops and commercializes RNA interference (RNAi) therapeutics for the treatment of genetically defined diseases. Headquartered in Cambridge, Massachusetts, the company pioneered the translation of RNAi biology into medicines that silence disease-causing genes. Alnylam's commercial portfolio includes ONPATTRO for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and AMVUTTRA for transthyretin-mediated amyloidosis polyneuropathy. The company also markets LEQVIO, a treatment for high cholesterol, through a partnership with Novartis. Alnylam operates a robust pipeline targeting rare diseases across hepatic, cardio-renal, pulmonary, central nervous system, and ocular therapeutic areas. The company employs approximately 2,500 people globally and maintains research and manufacturing facilities in North America and Europe. In recent developments, Alnylam continues expanding its approved product indications and advancing clinical programs for conditions including Stargardt disease, Alzheimer's disease, and hypertension. The company reported total revenues exceeding $1.3 billion in 2023, driven by strong commercial product uptake. Alnylam has established itself as the leading RNAi therapeutics company, with over 20 years of experience in the field and multiple regulatory approvals demonstrating the platform's clinical validation.